BREAKOUT SESSION DISCUSSION QUESTIONS

To foster conversation, participants will be placed in breakout rooms after brief presentations for small group live discussion. After the break-out sessions, participants will rejoin the main session for report-outs.

Note: Group assignments will be provided closer to the meeting date. For Session 1, each group is assigned a perspective and some questions will vary. For session 2, all groups will respond to the same questions.

SESSION 1: DEFINITIONS, DIAGNOSTICS CRITERIA, AND GAPS

Group 1: Clinical, pathology, and histology perspective

Moderator: Stephane Heymans, MD, PhD

Discussion Questions:

1. **Do you agree we need new definitions? Do you agree with the proposed definitions wording? Is further clarification needed? If not, what would you change?**

2. **What are the challenges and gaps in current definitions and diagnosis of myocarditis?**
   - What is the burden (acute and chronic) of myocarditis? How would it change?
   - What are the risk markers?
   - Do we need to be doing more myocardial biopsy (in the U.S.)?

3. **What can ACC do to improve the understanding of the definition and classification of myocarditis/what role should ACC play in disseminating information?**

Group 2: Imaging Perspective

Moderator: Bettina Heidecker, MD, FACC

Discussion Questions:

1. **Do you agree we need new definitions? Do you agree with the proposed definitions wording? Is further clarification needed? If not, what would you change?**

2. **What are the challenges and gaps in current definitions and diagnosis of myocarditis?**
   - What is the burden (acute and chronic) of myocarditis? How would it change with imaging being incorporating in diagnostic criteria?
   - What are the risk markers?
   - How can we make imaging more available? What are the costs, and how can they be covered?
   - Obtaining MRI is still challenging in many hospitals due to cost and availability. Would guideline recommendations make it easier to order an MRI at your hospital?
   - What is your preferred imaging modality? How frequently do you use PET-CT and for which indications? Do you see a role for PET-MRI? What is the role of MRI for prognostic assessment in myocarditis and for prevention of sudden cardiac death?

3. **What can ACC do to improve the understanding of the definition and classification of myocarditis/what role should ACC play in disseminating information?**

Group 3: Evolving biomarkers and genetics perspective

Moderator: Amy Kontorovich, MD, PhD, FACC

Discussion Questions:

1. **Do you agree we need new definitions? Do you agree with the proposed definitions wording? Is further clarification needed? If not, what would you change?**

2. **What are the challenges and gaps in current definitions and diagnosis of myocarditis?**
   - What are the risk markers?
   - How do absolute levels and/or trends in troponin and BNP inform classification and decision making? Troponin I vs. Troponin T (i.e. for immune check point inhibitor vs. other forms)? Should we be using high sensitivity troponin and NT-pro-BNP as standard of practice?
   - Should you assess ESR, hsCRP and/or other inflammatory markers (i.e. all myocarditis or only myopericarditis)? If so, when?
   - When should referral be considered for genetic evaluation (clinical context, family history, timing of performing genetic testing- acute vs. post-acute illness)? Which genes?
   - Does a "positive" genetic result change classification or plan of action?

3. **What can ACC do to improve the understanding of the definition and classification of myocarditis/what role should ACC play in disseminating information?**

Group 4: Patients' and caregivers' perspective

Moderator: Leslie T. Cooper, Jr., MD, FACC

Discussion Questions:

1. **Do you agree we need new definitions? Do you agree with the proposed definitions wording? Is further clarification needed? If not, what would you change?**

2. **What are the challenges and gaps in current definitions and diagnosis of myocarditis?**
   - What was it about the disease that was most impactful in your life?
   - What do patients need to better under their myocarditis diagnosis?

3. **What can ACC do to improve the understanding of the definition and classification of myocarditis/what role should ACC play in disseminating information?**

Group 5: Payers' and coverage perspective

Moderator: W.H. Wilson Tang, MD, FACC

Discussion Questions:

1. **Do you agree we need new definitions? Do you agree with the proposed definitions wording? Is further clarification needed? If not, what would you change?**

2. **What are the challenges and gaps in current definitions and diagnosis of myocarditis?**
   - What is the burden (acute and chronic) of myocarditis? How would it change?
   - What specific steps can the ACC take to engage policy makers and the coding community to encourage the adoption of standardized definitions for the various clinical terms used?
   - What is needed to ensure adequate coverage for diagnostic and therapeutic approaches for myocarditis, myopericarditis, inflammatory cardiomyopathies?

3. **What can ACC do to improve the understanding of the definition and classification of myocarditis/what role should ACC play in disseminating information?**

Group 6: Health inequity, disparities, and role of social determinants of health perspective

Moderator: Biykem Bozkurt, MD, PhD, FACC

Discussion Questions:

1. **Do you agree we need new definitions? Do you agree with the proposed definitions wording? Is further clarification needed? If not, what would you change?**

2. **What are the challenges and gaps in current definitions and diagnosis of myocarditis?**
   - What are the challenges and gaps in the diagnosis of myocarditis among underrepresented and disadvantaged populations?
   - Does the absence of a standard definition and diagnostic criteria play a role in health inequity, disparities, and role of social determinants of health in patients with myocarditis?

3. **What can ACC do to improve the understanding of the definition and classification of myocarditis/what role should ACC play in disseminating information?**

SESSION 2: MANAGEMENT STRATEGIES OF MYOCARDITIS

Groups 1-6

Discussion Questions:

1. What are the challenges and gaps in current management and treatment strategies of myocarditis?

2. What are the strengths and potential challenges of the proposed management? Would the algorithms proposed be feasible in your hospital/clinic? Would they be covered by insurance companies?

3. How do we know that the myocarditis has resolved especially when repeat diagnostic strategies are not covered?

4. What do you think is needed in future research, registry, and clinical trials for targeted therapies?

5. What outreach efforts should the ACC engage in to educate patients and non-cardiology providers ? How can ACC best engage and stimulate multiples stakeholders (cardiology and non-cardiology, other healthcare providers, guideline writing committees, policy makers, coding community, etc.) to standardize the terminology and treatment strategies?